Get the Stockscreener App
3.13
4.14%
0.14
Black Diamond Therapeutics Inc stock is traded at $3.13, with a volume of 496.20K.
It is up +4.14% in the last 24 hours and down -16.97% over the past month.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.99
Open:
$3.13
24h Volume:
496.20K
Relative Volume:
0.42
Market Cap:
$182.86M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.3728
EPS:
-2.28
Net Cash Flow:
$-66.75M
1W Performance:
+8.87%
1M Performance:
-16.97%
6M Performance:
-55.26%
1Y Performance:
+63.88%
1-Day Range:
$3.04
$3.37
1-Week Range:
$2.735
$3.37
52-Week Range:
$1.62
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat
Black Diamond Therapeutics Inc (BDTX) looking to reclaim success with recent performance - SETE News
Investing in Black Diamond Therapeutics Inc (BDTX) Is Getting More Attractive - Knox Daily
Results from Black Diamond Therapeutics Inc (BDTX) show potential - US Post News
Market Update: Black Diamond Therapeutics Inc (BDTX) Sees Negative Movement, Closing at 3.33 - The Dwinnex
Dimensional Fund Advisors LP Has $932,000 Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87 - Knox Daily
FY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by Analyst - MarketBeat
Analysts’ Recent Ratings Changes for Black Diamond Therapeutics (BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) is looking forward to a strong quarter - SETE News
Cuts for Black Diamond as runway's end nears - The Pharma Letter
Q3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Issued By Wedbush - MarketBeat
Layoffs at local cancer drug developer; Flagship names new managing partner - The Business Journals
Black Diamond Therapeutics (NASDAQ:BDTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data (BDTX) - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway - Investing.com India
Black Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at Wedbush - MarketBeat
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares - Investing.com Canada
Black Diamond Therapeutics Inc (BDTX) Becoming More Attractive for Investors - Knox Daily
Black Diamond Therapeutics Inc (BDTX) stock analysis: A simple moving average approach - US Post News
Market Highlights: Black Diamond Therapeutics Inc (BDTX) Ends on a Low Note at 3.66 - The Dwinnex
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - ForexTV.com
Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program - TipRanks
Black Diamond Therapeutics to Cut Jobs Amid Restructuring, Names New CFO - MarketWatch
Black Diamond CFO departs as part of restructuring, job cuts - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway By Investing.com - Investing.com Canada
Black Diamond Therapeutics Announces Restructuring Plan to - GlobeNewswire
Black Diamond Therapeutics Inc [NASDAQ: BDTX] Sees Decrease in Stock Value - Knox Daily
Black Diamond Therapeutics Inc (BDTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
It is Poised to be a Bull Market for Black Diamond Therapeutics Inc (BDTX) - SETE News
Analyzing Black Diamond Therapeutics Inc (BDTX) After Recent Trading Activity - Knox Daily
Stock Surge: Black Diamond Therapeutics Inc (BDTX) Closes at 4.23, Marking a -4.08 Increase/Decrease - The Dwinnex
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - US Post News
A company insider recently sold 221,600 shares of Black Diamond Therapeutics Inc [BDTX]. Should You Sale? - Knox Daily
A look into Black Diamond Therapeutics Inc (BDTX)’s deeper side - SETE News
Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BlackGold Secures Critical Extension for Proposal - TipRanks
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wave claims early lead in second-generation exon 53 skipping - BioCentury
Black Diamond Therapeutics Inc (BDTX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Black Diamond Therapeutics (NASDAQ:BDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Black Diamond shares hold buy rating on Phase 2 results - Investing.com India
BlackLine ticks higher as board appointment stokes some takeover speculation - Seeking Alpha
Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):